Cytokinetics (CYTK) Reports In-Line Q3 EPS

Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Cytokinetics (CYTK) PT Raised to $103 at JPMorgan